Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 33,055 Shares

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 33,055 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $2,674,149.50. Following the completion of the sale, the insider now directly owns 138,053 shares in the company, valued at $11,168,487.70. This trade represents a 19.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, January 14th, Martina M.D. Flammer sold 1,384 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total value of $95,108.48.
• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The shares were sold at an average price of $63.64, for a total value of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Stock Down 1.0 %

INSM traded down $0.83 during trading hours on Friday, reaching $79.95. 1,690,520 shares of the stock traded hands, compared to its average volume of 1,955,787. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $82.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a market cap of $14.30 billion, a price-to-earnings ratio of -14.41 and a beta of 1.11. The firm’s fifty day simple moving average is $72.79 and its two-hundred day simple moving average is $73.10.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently bought and sold shares of INSM. Vestal Point Capital LP boosted its stake in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after buying an additional 850,000 shares during the last quarter. TimesSquare Capital Management LLC acquired a new position in Insmed during the 3rd quarter worth $35,322,000. Assenagon Asset Management S.A. increased its position in shares of Insmed by 119.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 857,360 shares of the biopharmaceutical company’s stock worth $62,587,000 after purchasing an additional 466,306 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Insmed by 209.9% during the third quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company’s stock worth $33,285,000 after purchasing an additional 308,819 shares during the last quarter. Finally, Westfield Capital Management Co. LP acquired a new position in Insmed in the third quarter worth about $18,377,000.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on INSM shares. Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Guggenheim lifted their price objective on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Friday. JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Truist Financial reaffirmed a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.